UK, US & Canada Regulators Explain Why Decentralized Trials May Get A Closer Look

Decentralized clinical trials are subject to the same regulatory requirements as traditional site-based trials, but are of special interest to regulators because they represent a new way of working.

Businessman find a solution to increase profit
Decentralized Trials Can Be More Complex Than Conventional Site-Based Trials • Source: Shutterstock

While the use of decentralized elements in clinical trials is gaining momentum, a common refrain by sponsors wanting to experiment with new approaches on this front is that regulators tend to review such studies more aggressively than traditional trials conducted at investigative sites.

Decentralized clinical trials (DCTs) include elements that allow some or all trial-related tasks to be conducted in or a near a trial participant’s home

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D